Personalized circulating tumor DNA dynamics inform survival and response to immune checkpoint blockade in recurrent/metastatic head and neck cancer



Summary

This study investigates the utility of personalized circulating tumor DNA (ctDNA) monitoring in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs). The research found that changes in ctDNA levels during ICI therapy correlate with survival outcomes. Specifically, early ctDNA clearance predicted improved overall survival, while sustained ctDNA presence or increases indicated poorer prognosis. Furthermore, ctDNA dynamics were associated with clinical response, suggesting its potential as a predictive biomarker for ICI efficacy. This personalized approach to ctDNA monitoring could inform treatment decisions and improve patient management in R/M HNSCC.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!